Amphastar Pharmaceuticals recently announced it had entered a ten-year exclusive distribution agreement with Nanjing Chengong Pharmaceutical to market and sell its nasal powder product, BAQSIMI, ...
Amphastar Pharmaceuticals reported its third-quarter 2025 results, revealing quarterly revenues of US$191.84 million and net income of US$17.35 million, with sales of Baqsimi and Primatene Mist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback